SYNERLAB will manufacture
the 1st nicotine e-substitute
SYNERLAB Group and its Sophartex production site, located in Dreux, specializing in the manufacture of sachets and liquid forms, have been chosen by Dal Lab to develop and manufacture the first nicotine e-substitute.
Dal Lab, a Medical Device technology company specializing in smoking cessation, was created in 2019. Faced with the challenges of smoking and the still unmet needs in terms of smoking cessation solutions, Dal Lab has made it its mission to develop and implement the first high-dose nicotine e-substitute on the market, delivered exclusively in pharmacies.
The European market for smoking cessation aids, including e-cigarettes, is expected to reach US$18.63 billion by 2028, from US$7 billion in 2021; it should grow by 14.8% per year from 2021 to 2028. E-cigarettes represent just over 50% of this market.
The choice of SYNERLAB Sophartex was made on the skills in pharmaceutical development, the flexibility and the ability of the teams to mobilize in record time to respond to a Med-Tech attentive to soon introduce an innovative and safe product on the market.
It is a real transformation project for the SYNERLAB Sophartex site, creator of future jobs, and a great satisfaction for the teams concerned to be able to join forces with Dal Lab and thus combine its role as a pharmaceutical player by marketing a differentiating nicotine withdrawal product.
The site team was associated with the choice of components and the adaptation for the pharmaceutical market of machines that allow the filling, packaging and assembly of e-cigarettes, a first in France, with the level of Quality and Safety expected for a drug. The first machine intended for the registration batches should be received in June at the Vernouillet site.
"Thanks to an outstanding collaboration between SYNERLAB Sophartex and Dal Lab teams, in a spirit of industrial start-up, we want to develop and produce in record time an innovating and unheard of product in France while sticking to the necessary agenda of safety and regulations", comments Bruce Vielle, CEO of the SYNERLAB Group.
RELATED MaaT Pharma and Skyepharma will build a cGMP manufacturing plant for ecosystem microbiome-based therapeutics